ClinicalTrials.Veeva

Menu

Evaluation of HEArt invoLvement in Patients With FABRY Disease (HEAL-FABRY)

W

Wuerzburg University Hospital

Status

Enrolling

Conditions

Fabry Disease
Rare Diseases
Hypertrophic Cardiomyopathy
Fabry Disease, Cardiac Variant

Study type

Observational

Funder types

Other

Identifiers

NCT03362164
FAZiT-2001

Details and patient eligibility

About

This study evaluates predictors for the incidence of arrhythmias and sudden cardiac death as well as terminal heart failure in patients with Fabry disease.

Full description

Fabry disease is a rare disease and part of the group of lysosomal storage disorders. Natural history of Fabry disease has proven poor survival to ages >50 years outlining the importance to evaluate cardiac symptoms and outcomes of patients with Fabry disease.

This study is a prospective cohort study and observes patients since 2001. Through this long-term experience and the relative high number of patients this study is suggested to help estimating the risk of cardiac arrhythmias and sudden cardiac death (SCD) as well as death or heart transplantation due to terminal heart failure.

All patients in treatment in the Fabry Center Wuerzburg (FAZiT) are included in this study if informed consent is provided.

Enrollment

650 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Fabry disease (genetically confirmed)
  • Signed informed consent
  • 18 years and older

Exclusion criteria

  • No informed consent
  • Withdrawal of informed consent

Trial contacts and locations

1

Loading...

Central trial contact

Jonas Muentze, MD; Peter Nordbeck, MD, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems